{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:22:16Z","timestamp":1792858936008,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.abd.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T09:35:12Z","timestamp":1684834512000},"page":"656-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["JAK-STAT pathway inhibitors in dermatology"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-9294","authenticated-orcid":false,"given":"H\u00e9lio Amante","family":"Miot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-6099","authenticated-orcid":false,"given":"Paulo Ricardo","family":"Criado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-5765","authenticated-orcid":false,"given":"Caio C\u00e9sar Silva","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-3128","authenticated-orcid":false,"given":"Mayra","family":"Ianhez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2283-069X","authenticated-orcid":false,"given":"Carolina","family":"Talhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-414X","authenticated-orcid":false,"given":"Paulo M\u00fcller","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.03.001_bib0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: part I. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-811X-2-8","article-title":"The STATs in cell stress-type responses","volume":"2","author":"Dudley","year":"2004","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.abd.2023.03.001_bib0015","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: part II. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK-STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.abd.2023.03.001_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic Mechanisms of JAK Inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2249.1992.tb07922.x","article-title":"Cytokine receptors: structure and signal transduction","volume":"90","author":"Foxwell","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41232-022-00221-x","article-title":"Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases-RA as a role model","volume":"42","author":"Takeuchi","year":"2022","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.abd.2023.03.001_bib0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.abd.2023.03.001_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071971","article-title":"JAK-STAT signalling pathway in cancer","volume":"12","author":"Brooks","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.abd.2023.03.001_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00862-21","article-title":"SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway","volume":"95","author":"Chen","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.abd.2023.03.001_bib0060","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.molmed.2020.06.007","article-title":"JAK-STAT targeting offers novel therapeutic opportunities in sepsis","volume":"26","author":"Clere-Jehl","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ijc.32123","article-title":"JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma","volume":"145","author":"Dolatabadi","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.abd.2023.03.001_bib0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/01443615.2020.1824215","article-title":"Portal venous thrombosis associated with JAK 2 mutation in pregnancy \u2014 case report","volume":"41","author":"Barbosa","year":"2021","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.abd.2023.03.001_bib0075","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s10875-021-01051-1","article-title":"STAT3 Hyper-IgE syndrome\u2014an update and unanswered questions","volume":"41","author":"Tsilifis","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.abd.2023.03.001_bib0090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0095","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.abd.2023.03.001_bib0100","first-page":"1485","article-title":"Pharmacology of inhibitors of Janus kinases \u2014 part 1: pharmacokinetics","volume":"20","author":"Eichner","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2023.03.001_bib0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1016730","article-title":"Hypersensitivity reactions to small molecule drugs","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0110","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S1470-2045(16)30312-6","article-title":"21st century pharmacovigilance: efforts, roles, and responsibilities","volume":"17","author":"Pitts","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.abd.2023.03.001_bib0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-020-00275-8","article-title":"Frequency of prescription claims for drugs that may interact with janus kinase inhibitors among patients with rheumatoid arthritis in the US","volume":"8","author":"Walton","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061567","article-title":"Herb-drug interaction in inflammatory diseases: review of phytomedicine and herbal supplements","volume":"11","author":"Lippert","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0009-9236(01)00127-8","article-title":"The effects of St. John\u2019s wort (Hypericum perforatum) on human cytochrome P450 activity","volume":"70","author":"Wang","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","article-title":"PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD","volume":"14","author":"Gilardi","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.abd.2023.03.001_bib0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","article-title":"Assessment of the effects of inhibition or induction of CYP2C19 and CYP2C9 enzymes, or inhibition of OAT3, on the pharmacokinetics of abrocitinib and its metabolites in healthy individuals","volume":"47","author":"Wang","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.abd.2023.03.001_bib0145","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jcph.1858","article-title":"Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites","volume":"61","author":"Wang","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.abd.2023.03.001_bib0150","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2017.1359256","article-title":"Efficacy of baricitinib in the treatment of rheumatoid arthritis","volume":"18","author":"Richez","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.abd.2023.03.001_bib0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical atassessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis trement","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.abd.2023.03.001_bib0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.1980","article-title":"Effects of renal impairment on the pharmacokinetics of abrocitinib and its metabolites","volume":"62","author":"Wang","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.abd.2023.03.001_bib0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.03.001_bib0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.03.001_bib0185","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.abd.2023.03.001_bib0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ad.2022.03.025","article-title":"JAK inhibitors in atopic dermatitis associated with risk of viral infections: a critical appraisal","volume":"114","author":"Pathania","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2023.03.001_bib0195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0200","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0205","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/09546634.2020.1839008","article-title":"Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials","volume":"33","author":"Reich","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.03.001_bib0210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40257-021-00604-9","article-title":"Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes","volume":"22","author":"Silverberg","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0215","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0225","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1097\/RHU.0000000000001749","article-title":"The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis","volume":"28","author":"Alves","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/OARRR.S322086","article-title":"Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis","volume":"13","author":"Bertoldi","year":"2021","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0235","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.03.001_bib0240","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","article-title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0250","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-247276","article-title":"Herpes zoster meningitis in a rheumatoid arthritis patient treated with tofacitinib","volume":"15","author":"Nakamura","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.abd.2023.03.001_bib0255","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40268-021-00349-0","article-title":"Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies?","volume":"21","author":"Speeckaert","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.abd.2023.03.001_bib0260","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.03.001_bib0265","doi-asserted-by":"crossref","first-page":"eCE0196","DOI":"10.31744\/einstein_journal\/2022CE0196","article-title":"The rise of tuberculosis: regression in combating advances as a legacy of COVID-19?","volume":"20","author":"Barros","year":"2022","journal-title":"Einstein (Sao Paulo)"},{"issue":"Suppl 3","key":"10.1016\/j.abd.2023.03.001_bib0270","doi-asserted-by":"crossref","first-page":"94","DOI":"10.37201\/req\/s03.20.2022","article-title":"Latent tuberculosis infection: approach and therapeutic schemes","volume":"35","author":"Fortun","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.abd.2023.03.001_bib0275","first-page":"1046","article-title":"Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration","volume":"28","author":"Qian","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.abd.2023.03.001_bib0280","first-page":"4","article-title":"Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications","volume":"27","author":"Shalabi","year":"2022","journal-title":"Skin Ther Lett"},{"key":"10.1016\/j.abd.2023.03.001_bib0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.03.001_bib0290","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ibd\/izab056","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of nonmelanoma skin cancer rates from the ulcerative colitis clinical program","volume":"28","author":"Sands","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.abd.2023.03.001_bib0300","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41423-019-0320-3","article-title":"JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis","volume":"17","author":"Nocturne","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0305","first-page":"1","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.abd.2023.03.001_bib0310","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/1346-8138.16635","article-title":"English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis","volume":"50","author":"Saeki","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5935\/abc.20170121","article-title":"Atualiza\u00e7\u00e3o da diretriz brasileira de dislipidemias e preven\u00e7\u00e3o da aterosclerose \u2014 2017","volume":"109","author":"Faludi","year":"2017","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.abd.2023.03.001_bib0320","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.rmed.2015.10.005","article-title":"The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis","volume":"109","author":"Okamoto","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0325","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1007\/s12325-022-02120-6","article-title":"Epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide israeli healthcare provider database","volume":"39","author":"Weil","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0330","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic dermatitis: pathophysiology","volume":"1027","author":"David Boothe","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.abd.2023.03.001_bib0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0340","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0345","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.abd.2023.03.001_bib0350","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results","volume":"149","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0355","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0360","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/10600280221103282","article-title":"Review of ruxolitinib in the treatment of atopic dermatitis","volume":"57","author":"Mohney","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.abd.2023.03.001_bib0365","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0370","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0375","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0380","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"ilverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.abd.2023.03.001_bib0385","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/jdv.18816","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.abd.2023.03.001_bib0390","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1111\/jdv.18804","article-title":"Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis","volume":"37","author":"Vittrup","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.03.001_bib0395","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0400","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2023.03.001_bib0405","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.abd.2023.03.001_bib0410","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0415","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/1346-8138.16126","article-title":"Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: a network meta-analysis","volume":"48","author":"Zhang","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0420","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0425","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062979","article-title":"Psoriasis: pathogenesis, comorbidities, and therapy updated","volume":"22","author":"Kanda","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.abd.2023.03.001_bib0430","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1111\/ced.15360","article-title":"Understanding psoriasis: the development of the immune pathogenesis","volume":"47","author":"Papadopoullos","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0435","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0440","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.abd.2023.03.001_bib0445","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis \u2014 a network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.03.001_bib0450","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0455","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0460","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.abd.2023.03.001_bib0465","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.abd.2023.03.001_bib0470","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0475","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0480","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0485","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0490","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17512433.2020.1702878","article-title":"JAK inhibition in the treatment of alopecia areata \u2014 a promising new dawn?","volume":"13","author":"Ismail","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.abd.2023.03.001_bib0495","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/jdv.18810","article-title":"Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors","volume":"37","author":"Gupta","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.03.001_bib0500","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2023.03.001_bib0505","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2023.03.001_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100156","article-title":"Safety and efficacy of ritlecitinib and brepocitinib in alopecia areata: results from the crossover open-label extension of the ALLEGRO phase 2a trial","volume":"2","author":"King","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.abd.2023.03.001_bib0515","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0520","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors \u2014 a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0525","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.abd.2023.03.001_bib0530","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata","volume":"315","author":"Mikhaylov","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2023.03.001_bib0535","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.abd.2020.05.006","article-title":"Consensus on the treatment of alopecia areata \u2014 Brazilian Society of Dermatology","volume":"95","author":"Ramos","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0540","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","article-title":"Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site","volume":"80","author":"van den Wijngaard","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.abd.2023.03.001_bib0545","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.abd.2021.09.008","article-title":"Update on the pathogenesis of vitiligo","volume":"97","author":"Marchioro","year":"2022","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0550","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ymthe.2022.04.019","article-title":"RNAi-based modulation of IFN-gamma signaling in skin","volume":"30","author":"Tang","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0555","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/1523-1747.ep12338641","article-title":"Interleukin-15 mRNA is expressed by human keratinocytes Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation","volume":"106","author":"Blauvelt","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0560","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.abd.2023.03.001_bib0565","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0570","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.abd.2019.08.032","article-title":"Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation","volume":"95","author":"Komnitski","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0575","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000513938","article-title":"Topical tofacitinib: A Janus Kinase inhibitor for the treatment of vitiligo in an adolescent patient","volume":"13","author":"Berbert Ferreira","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0580","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.abd.2023.03.001_bib0585","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.abd.2023.03.001_bib0590","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2023.03.001_bib0595","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0600","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/1346-8138.14879","article-title":"Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo","volume":"46","author":"Hayashi","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0605","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.1994.tb08590.x","article-title":"Determination of density of follicles on various regions of the face by cyanoacrylate biopsy: correlation with sebum output","volume":"131","author":"Pagnoni","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0610","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/jid.2015.126","article-title":"Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors","volume":"135","author":"Goldstein","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0615","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0620","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","article-title":"Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo","volume":"142","author":"Pandya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0625","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1067\/mjd.2001.114752","article-title":"Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo","volume":"44","author":"Scherschun","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0630","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2023.03.001_bib0635","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0640","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0645","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0650","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0655","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/17512433.2020.1709825","article-title":"Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum","volume":"13","author":"Goldust","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.abd.2023.03.001_bib0660","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ced.14683","article-title":"Tofacitinib for the treatment of refractory pyoderma gangrenosum","volume":"46","author":"Orfaly","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100099","article-title":"Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor","volume":"4","author":"Scheinberg","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.abd.2023.03.001_bib0670","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0675","first-page":"504","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.03.001_bib0680","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: a concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.03.001_bib0685","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760199","article-title":"Kinase inhibition as treatment for acute and chronic graft-versus-host disease","volume":"12","author":"Braun","year":"2021","journal-title":"Front Immunol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:42:44Z","timestamp":1759794164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059623001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":137,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0365059623001149"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.03.001","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK-STAT pathway inhibitors in dermatology","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}